^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    GASTROClear Test

    Company:
    MiRXES
    Type:
    CE Marked
    Details
    Evidence

    News

    over1year
    Mirxes receives FDA’s Breakthrough Device Designation for GASTROClearTM to advance blood-based cancer early detection (Mirxes Press Release)
    "Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd...announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)."
    FDA event
    |
    GASTROClear Test
    over1year
    MiRxes gets $50M in Series D funding, applies to Hong Kong Limited stock exchange (Genomeweb)
    "MiRxes said Wednesday that it has completed a Series D funding round totaling $50 million, which will help accelerate the Singapore-based firm's development of cancer early detection blood tests and other preventive healthcare solutions."
    Financing
    |
    GASTROClear Test
    over2years
    DIAGNOSTIC PERFORMANCE OF GASTROCLEAR FOR DETECTING GASTRIC CANCER IN THE JAPANESE POPULATION (UEGW 2022)
     GASTROClear yielded a competent diagnostic ability for GC in the Japanese population and has a potential to contribute to efficient stratification for the risk of GCs.
    Clinical
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    GASTROClear Test